BHST Nasdaq Pharmaceutical Preparations Financials FY2023βFY2025
Bioharvest Sciences Inc. had $34.5M of revenue in fiscal 2025, up 37.0% on the year before.
Hi! I read Bioharvest Sciences Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+37.0%
Yes. Sales grew 37.0% last year.
Does it make a profit?
β32.3%
No. It lost money last year.
Does profit turn into cash?
β27.8%
No. It spent more cash than it brought in.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
KIRA Β· Bioharvest Sciences Inc. had $34.5M of revenue in fiscal 2025, up 37.0% on the year before. Its operating margin was β16.2%, up 11.6Β pts: of every 100 in sales, about β16 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Margins, % of revenue
KIRA Β· Bioharvest Sciences Inc. lost $11.1M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$9.6M in fiscal 2025, β27.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
KIRA Β· Bioharvest Sciences Inc. has $22.9M more cash than debt.
Cash, debt and the ratios that show how comfortably Bioharvest Sciences Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $5.4M | $2.4M | $23.0M |
| Debt incl. finance leases | $0.0M | $3.9M | $0.1M |
| Debt / equity | β | 2.9x | 0.0x |
| Current ratio | 0.3x | 0.6x | 4.0x |
| Quick ratio | 0.2x | 0.3x | 3.4x |
| Total liabilities | $29.9M | $23.7M | $22.2M |
| Shareholders' equity | β$14.9M | $1.3M | $25.4M |
| Net debt (β = net cash) | β$5.4M | $1.5M | β$22.9M |
KIRA Β· Its return on capital was β171.2%: every 100 invested in the business earned about β171 in a year.
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 5 | β / 5 |
| Accruals ratio | β | β | β |
| Altman Z'' | β | β | β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $12.7M | $25.2M | $34.5M |
| Gross profit | $5.6M | $13.9M | $20.5M |
| Operating income | β$10.0M | β$7.0M | β$5.6M |
| Pretax income | β$12.6M | β$12.9M | β$11.1M |
| Income tax | $0.0M | β$0.0M | β$0.1M |
| Net income | β$12.6M | β$12.9M | β$11.1M |
| Cash flow | |||
| Cash from operations | β$8.5M | β$6.7M | β$7.2M |
| Capital expenditure | $1.5M | $2.8M | $2.4M |
| Free cash flow | β$10.0M | β$9.5M | β$9.6M |
| Depreciation and amortization | $0.8M | $1.3M | $1.6M |
| Stock-based compensation | $0.6M | $0.6M | β |
| Balance sheet | |||
| Cash and short-term investments | $5.4M | $2.4M | $23.0M |
| Total debt | $0.0M | $3.9M | $0.1M |
| Current assets | $9.1M | $7.9M | $30.5M |
| Current liabilities | $26.5M | $14.3M | $7.7M |
| Inventory | $2.5M | $3.7M | $4.6M |
| Property and equipment, net | $3.9M | $7.8M | $8.3M |
| Total liabilities | $29.9M | $23.7M | $22.2M |
| Shareholders' equity | β$14.9M | $1.3M | $25.4M |
| Margins | |||
| Gross margin | 44.5% | 55.4% | 59.3% |
| Operating margin | β78.6% | β27.7% | β16.2% |
| EBITDA margin | β72.0% | β22.8% | β11.4% |
| Net margin | β99.1% | β51.3% | β32.3% |
| FCF margin | β78.9% | β37.8% | β27.8% |
| Returns | |||
| Return on capital | β | β194.1% | β171.2% |
| Return on equity | β | β | β83.2% |
| Return on tangible equity | β | β970.9% | β43.8% |
| Growth | |||
| Revenue growth | β | 98.8% | 37.0% |
| Financial health | |||
| Debt / equity | β | 2.9x | 0.0x |
| Current ratio | 0.3x | 0.6x | 4.0x |
| Quick ratio | 0.2x | 0.3x | 3.4x |
| Capital allocation | |||
| Capex / revenue | 11.6% | 11.3% | 6.8% |
| Stock comp / revenue | 4.4% | 2.4% | β |
Source: SEC EDGAR XBRL filings (CIK 0001723464). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
